Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

December 04, 2025

From Denali Therapeutics Inc.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

3 Mid-Cap Stocks That Concern Us

December 03, 2025

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

How Do Investors Really Feel About Royalty Pharma? ↗

September 16, 2025

Via Benzinga

Royalty Pharma to Present at Upcoming Investor Conferences

November 26, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

3 Value Stocks with Warning Signs

November 17, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Topics Supply Chain

3 Low-Volatility Stocks We Find Risky

November 16, 2025

Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%.

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?

November 12, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Stocks Supply Chain

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Topics Intellectual Property

Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗

November 05, 2025

Royalty Pharma's Q3 2025 earnings beat estimates, with strong revenue and EPS. The company also raised its full-year 2025 guidance.

Via Chartmill

Topics Earnings

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗

November 05, 2025

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing...

Via Benzinga

Topics Economy

Royalty Pharma Reports Third Quarter 2025 Results

November 05, 2025

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

November 04, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for.

Topics Artificial Intelligence Intellectual Property

What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings

November 03, 2025

ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗

Topics Artificial Intelligence

November 01, 2025

RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance.

Via Chartmill

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗

October 31, 2025

Via MarketBeat

2 Reasons to Avoid RPRX and 1 Stock to Buy Instead

October 29, 2025

While the S&P 500 is up 23.9% since April 2025, Royalty Pharma (currently trading at $36.80 per share) has lagged behind, posting a return of 12.5%. This was partly due to its softer quarterly results...

Topics Government Stocks Supply Chain

1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗

October 28, 2025

Via MarketBeat

Royalty Pharma Declares Fourth Quarter 2025 Dividend

October 17, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the...

3 Healthcare Stocks We Keep Off Our Radar

October 13, 2025

Topics Economy Stocks

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 09, 2025

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

September 29, 2025

Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum

September 19, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore

September 17, 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation

September 11, 2025

Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market

September 10, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges

September 08, 2025